Business
Quince Therapeutics Announces CPT: Pharmacometrics & Systems Pharmacology Publication of eDSP Population Pharmacokinetic Modeling Study
SOUTH SAN FRANCISCO, Calif., September 25, 2025--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, announced the publication of an advanced population pharmacokinetic (PK) modeling study of pediatric patients with Ataxia-Telangiectasia (A-T) and healthy adults treated with its Phase 3 lead asset, eDSP (dexamethasone sodium phosphate [DSP] encapsulated in a patient’s own red
About this update from Quince Therapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1121,"height":442,"url":"https://media.zenfs.com/en/business-wire.com/9cc06c67134e373682fb28bd15e251a5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/xn.uBtpd6MnQHXkHnYMDpw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM3OTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/9cc06c67134e373682fb28bd15e251a5","width":960,"height":379},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/5bXNYvLRn4Gkji5NXeM_Sw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIyNDI7aD04ODQ7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/9cc06c67134e373682fb28bd15e251a5","width":1121,"height":442}},"lazy":false},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., September 25, 2025--(BUSINESS WIRE)--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, announced the publication of an advanced population pharmacokinetic (PK) modeling study of pediatric patients with Ataxia-Telangiectasia (A-T) and healthy adults treated with its Phase 3 lead asset, eDSP (dexamethasone sodium phosphate [DSP] encapsulated in a patient’s own red blood cells), in the scientific journal CPT: Pharmacometrics & Systems Pharmacology (PSP). The journal is an official open access journal of the American Society for Clinical Pharmacology and Therapeutics (ASCPT).","length":734,"tagName":"p"},{"type":"text","content":"Giovanni Mambrini, MSc, Quince’s Chief Technology Officer, said, "We are pleased to continue to advance new research further elucidating the sustained release properties and demonstrated safety profile of our Phase 3 lead asset, eDSP, for the treatment of A-T. Notably, the data revealed eDSP's ability to maintain low, sustained plasma concentrations of DSP for 20 to 30 days without drug accumulation with the aim of providing efficacy while reducing the risk of toxic corticosteroid-related side effects. This PK modeling supports prediction of DSP drug exposure in children with A-T who may benefit from chronic corticosteroid administration to treat this devastating neurodegenerative rare disease."","length":718,"tagName":"p"},{"type":"text","content":"PSP Publication Highlights","length":26,"tagName":"p"},{"type"...